TY - JOUR
T1 - Precision Medicine Approaches to Cardiac Arrhythmias
T2 - JACC Focus Seminar 4/5
AU - Giudicessi, John R.
AU - Ackerman, Michael J.
AU - Fatkin, Diane
AU - Kovacic, Jason C.
N1 - Funding Information:
This work was supported by the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program. Dr. Fatkin has received support from the Victor Chang Cardiac Research Institute, Estate of the Late R.T. Hall, New South Wales Health, Australian Genomics, National Health and Medical Research Council of Australia. Dr. Kovacic has received research support from the National Institutes of Health (R01HL130423, R01HL135093, R01HL148167–01A1) and New South Wales Health (RG194194). Dr. Giudicessi has modest equity interest in 3M, GlaxoSmithKline, Medtronic, MyoKardia, and Pfizer. Dr. Ackerman is a consultant for Abbott, ARMGO Pharma, Audentes Therapeutics, Boston Scientific, Daiichi-Sankyo, Invitae, LQT Therapeutics, Medtronic, MyoKardia, and UpToDate; and he and the Mayo Clinic are involved in an equity/royalty relationship with AliveCor (AliveCor was not involved in this study).
Publisher Copyright:
© 2021 American College of Cardiology Foundation
PY - 2021/5/25
Y1 - 2021/5/25
N2 - In the initial 3 papers in this Focus Seminar series, the fundamentals and key concepts of precision medicine were reviewed, followed by a focus on precision medicine in the context of vascular disease and cardiomyopathy. For the remaining 2 papers, we focus on precision medicine in the context of arrhythmias. Specifically, in this fourth paper we focus on long QT syndrome, Brugada syndrome, and atrial fibrillation. The final (fifth) paper will deal with catecholaminergic polymorphic ventricular tachycardia. These arrhythmias represent a spectrum of disease ranging from common to relatively rare, with very different genetic and environmental causative factors, and with differing clinical manifestations that range from almost no consequences to lethality in childhood or adolescence if untreated. Accordingly, the emerging precision medicine approaches to these arrhythmias vary significantly, but several common themes include increased use of genetic testing, avoidance of triggers, and personalized risk stratification to guide the use of arrhythmia-specific therapies.
AB - In the initial 3 papers in this Focus Seminar series, the fundamentals and key concepts of precision medicine were reviewed, followed by a focus on precision medicine in the context of vascular disease and cardiomyopathy. For the remaining 2 papers, we focus on precision medicine in the context of arrhythmias. Specifically, in this fourth paper we focus on long QT syndrome, Brugada syndrome, and atrial fibrillation. The final (fifth) paper will deal with catecholaminergic polymorphic ventricular tachycardia. These arrhythmias represent a spectrum of disease ranging from common to relatively rare, with very different genetic and environmental causative factors, and with differing clinical manifestations that range from almost no consequences to lethality in childhood or adolescence if untreated. Accordingly, the emerging precision medicine approaches to these arrhythmias vary significantly, but several common themes include increased use of genetic testing, avoidance of triggers, and personalized risk stratification to guide the use of arrhythmia-specific therapies.
KW - atrial fibrillation
KW - Brugada syndrome
KW - cardiac arrhythmia
KW - genetic testing
KW - genetics
KW - long QT syndrome
KW - precision medicine
KW - sudden cardiac death
UR - http://www.scopus.com/inward/record.url?scp=85105563804&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2021.03.325
DO - 10.1016/j.jacc.2021.03.325
M3 - Review article
C2 - 34016268
AN - SCOPUS:85105563804
SN - 0735-1097
VL - 77
SP - 2573
EP - 2591
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 20
ER -